Lucentis (ranibizumab) / Roche, Novartis 
Welcome,         Profile    Billing    Logout  
 172 Diseases   135 Trials   135 Trials   7089 News 


«12...3940414243444546474849...7475»
  • ||||||||||  Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
    Journal:  Retinal Nonperfusion Characteristics on Ultra-Widefield Angiography in Eyes With Severe Nonproliferative Diabetic Retinopathy and Proliferative Diabetic Retinopathy. (Pubmed Central) -  Feb 24, 2020   
    Baseline images were obtained from 2 completed randomized clinical trials (Ranibizumab for Diabetic Macular Edema Panretinal Photocoagulation [RDP] study and Clinical Efficacy of Intravitreal Aflibercept vs Panretinal Photocoagulation for Best Corrected Visual Acuity in Patients With Proliferative Diabetic Retinopathy at 52 Weeks [CLARITY] study)...Eyes with NVD had the largest total area of retinal nonperfusion, with a difference of 65.1 DA (95% CI, 28.6 to 95.8 DA; P < .001) compared with eyes with only NVE. These findings suggest eyes with at least 107.3 DA of nonperfusion are at risk of proliferative disease, and eyes with NVD have the largest area of retinal nonperfusion.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Enrollment closed, Trial completion date, Monotherapy:  Stereotactic Radiotherapy for Wet AMD (STAR) (clinicaltrials.gov) -  Feb 24, 2020   
    P3,  N=411, Active, not recruiting, 
    Clinicians performing intravitreal injections must be aware of these associations for a better understanding of ACD and ECD changes in phakic eyes. Recruiting --> Active, not recruiting | Trial completion date: Mar 2024 --> Jun 2024
  • ||||||||||  Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
    Retrospective data, Journal:  Comparison of Intravitreal Aflibercept and Ranibizumab for Treatment of Myopic Choroidal Neovascularization: One-Year Results-A Retrospective, Comparative Study. (Pubmed Central) -  Feb 23, 2020   
    The mean BCVA significantly improved from baseline 1.54 ± 0.76 to 0.85 ± 0.61 and the mean CMT significantly decreased from baseline 384.3 ± 119.1 μm to 305.9 ± 75.4 μm to 305.9 ± 75.4 p : 0.024 and p : 0.024 and μm to 305.9 ± 75.4 μm to 305.9 ± 75.4 p : 0.024 and p : 0.024 and p : 0.024 and p : 0.024 and. Both IVA and IVR treatment modalities resulted in similar anatomical outcomes but IVA had better visual outcomes in treatment of mCNV.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Enrollment change:  Lucentis for New Onset Neovascular Glaucoma (clinicaltrials.gov) -  Feb 17, 2020   
    P1/2,  N=0, Withdrawn, 
    The patient improved with intravitreal ranibizumab. N=30 --> 0
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Retrospective data, Journal:  Sequence effect in the treatment of proliferative diabetic retinopathy with intravitreal ranibizumab and panretinal photocoagulation. (Pubmed Central) -  Feb 16, 2020   
    Central macular thickness reduction before the second panretinal photocoagulation session was significant in the intravitreal ranibizumab+ group (p < 0.05). The sequence used in intravitreal ranibizumab+ group showed clear advantages over that in panretinal photocoagulation+ group in the treatment of proliferative diabetic retinopathy, not only in the use of lower energy for panretinal photocoagulation but also in the more rapid regression of neovascularization and less need of additional treatment.
  • ||||||||||  Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
    Journal:  Impact of angiogenic activation and inhibition on miRNA profiles of human retinal endothelial cells. (Pubmed Central) -  Feb 16, 2020   
    In this study we characterized the miRNA profile of HRMVECs under resting, angiogenic and anti-angiogenic conditions and identified several miRNAs of potential pathophysiologic importance for angioproliferative retinal diseases. Our results have implications for possible miRNA-targeted angiomodulatory approaches in diseases like diabetic retinopathy or retinopathy of prematurity.
  • ||||||||||  Avastin (bevacizumab) / Roche, Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
    Journal:  Sustained Intraocular Pressure Rise after the Treat and Extend Regimen at 3 Years: Aflibercept versus Ranibizumab. (Pubmed Central) -  Feb 15, 2020   
    Male gender, South Asian ethnicity, older age, presence of AMD and vein occlusion, use of ranibizumab, higher number of injections, narrow angles, switch to bevacizumab/ranibizumab, and preexisting glaucoma were associated with sustained IOP rise...IOP rise is an important consideration as the chronicity of the condition can eventually lead to glaucomatous changes in eyes with already compromised vision. Follow-ups and use of appropriate therapy can be determined correspondingly.
  • ||||||||||  Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
    Journal:  Tachyphylaxis during treatment of exudative age-related macular degeneration with aflibercept. (Pubmed Central) -  Feb 14, 2020   
    Tachyphylaxis occurs after repeated IVA injections in a minority of patients with AMD for a long term and is more likely to occur in eyes with lesions beneath the retinal pigment epithelium and no intraretinal edema. Treatment of AMD should be performed keeping this fact in mind, while considering the consecutive treatment.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Trial completion date, Trial primary completion date:  MERIT: Macular Edema Ranibizumab v. Intravitreal Anti-inflammatory Therapy Trial (clinicaltrials.gov) -  Feb 10, 2020   
    P3,  N=240, Recruiting, 
    Systemic steroids may be a management option in patients with CNVM and RPE tear with recalcitrant SRF if there is no contraindication to their use. Trial completion date: Jul 2020 --> Jul 2021 | Trial primary completion date: Jan 2020 --> Jan 2021
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Clinical, Journal:  Durability of Diabetic Retinopathy Improvement with As-Needed Ranibizumab: Open-label Extension of RIDE and RISE Studies. (Pubmed Central) -  Jan 31, 2020   
    P3
    DR severity improvements with ranibizumab were maintained in the majority of patients in the OLE after switching from ranibizumab monthly to an individualized best-corrected visual acuity- and optical coherence tomography-based ranibizumab 0.5 mg PRN dosing regimen. Because nearly one-third of OLE patients not requiring further therapy for DME experienced DR worsening, once DME resolves, patients should be watched carefully for worsening of DR and possible need for more frequent follow-up and/or treatment of vision-threatening disease with anti-VEGF or other modalities.
  • ||||||||||  Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
    Journal:  Follow up at 5 Years of Non-Fibrotic Scars in the Comparison of Age-related Macular Degeneration Treatments Trials (CATT). (Pubmed Central) -  Jan 31, 2020   
    Because nearly one-third of OLE patients not requiring further therapy for DME experienced DR worsening, once DME resolves, patients should be watched carefully for worsening of DR and possible need for more frequent follow-up and/or treatment of vision-threatening disease with anti-VEGF or other modalities. These results indicate that, on average, eyes with NFS after anti-VEGF treatment have good visual acuity not only at 1 and 2 years, but also through 5 years.
  • ||||||||||  Avastin (bevacizumab) / Roche, Eylea (aflibercept intravitreal) / Regeneron, Lucentis (ranibizumab) / Roche, Novartis
    Trial completion date, Trial primary completion date:  SwapTwo: Treatment of Diabetic Macular Edema With Aflibercept in Subjects Previously Treated With Ranibizumab or Bevacizumab (clinicaltrials.gov) -  Jan 31, 2020   
    P4,  N=20, Recruiting, 
    Patients treated with a ranibizumab T&E protocol that tolerated some SRF achieved VA that is comparable, with fewer injections, to that achieved when treatment aimed to completely resolve all SRF. Trial completion date: Dec 2018 --> Dec 2020 | Trial primary completion date: Nov 2018 --> Nov 2020
  • ||||||||||  JNJ-1887 / J&J
    Enrollment closed:  AAVCAGsCD59 for the Treatment of Wet AMD (clinicaltrials.gov) -  Jan 31, 2020   
    P1,  N=25, Active, not recruiting, 
    Trial completion date: Dec 2018 --> Dec 2020 | Trial primary completion date: Nov 2018 --> Nov 2020 Recruiting --> Active, not recruiting
  • ||||||||||  Votrient (pazopanib) / Novartis, Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
    Journal:  Pazopanib Selectively Inhibits Choroidal Vascular Endothelial Cell Proliferation and Promotes Apoptosis. (Pubmed Central) -  Jan 26, 2020   
    Further, pazopanib actively inhibited proliferation of VEGF-enriched CVECs, with 1.32, 1.92, 1.92 and 4.1-fold increase (p<0.01) in intracellular caspase 3 levels. VEGF-enriched CVECs treated with escalating doses of pazopanib decreased cell viability and increased caspase 3 levels in a time and dose dependent manner.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Trial completion date, Trial termination:  Combination of Intravitreal Ranibizumab With or Without Macular Laser Photocoagulation for ME Secondary to BRVO (clinicaltrials.gov) -  Jan 22, 2020   
    P=N/A,  N=80, Terminated, 
    These results suggest that anti-VEGF injection influences the peripapillary choriocapillaris flow out of exudative lesions, and that its effects depend on the baseline status of the choroid and choriocapillaris. Trial completion date: Feb 2020 --> Jan 2019 | Not yet recruiting --> Terminated